ASTRAVA BIOSCIENCES
Space Pharmacology
Research notes on commercial space, microgravity life science, and cross-environment drug translation: translating external momentum into platform capabilities Astrava Bio can compound over time.
After WIRED reported Mass Balance’s autonomous orbital lab, the important question for Astrava is not one space experiment. It is how orbital data becomes repeatable, model-ready drug R&D evidence.
Read full article
If SpaceX turns Mars travel from science fiction into engineering reality, pharma must answer an untested question: will Earth-developed medicines remain reliable under microgravity, radiation, confinement, and distance from Earth?
Read full article
A space pharma company should not wait for a large off-world patient market. Its near-term business is turning extreme environments into evidence, models, IP, and platform assets that also improve Earth-based drug R&D.
Read full article
Low Earth orbit research is moving from scarce missions to a planned industrial interface. The real question is no longer whether something can fly, but which scientific questions deserve orbit.
Read full article
The value of microgravity is not only space manufacturing. It is making gravity a controllable perturbation for testing the robustness of drug mechanisms, formulations, and biomarkers.
Read full article
Ritonavir shows why solid form is not a minor manufacturing detail. It can reshape supply, quality risk, and process strategy; recent orbital Form III work brings this classic lesson into the microgravity era.
Read full article